Page 2 - Obesity

Liver fat, not bodyweight, predicts health risks in obese children: Study

Children with "unhealthy obesity" were three times more likely born from high-risk pregnancies, linking early-life factors to later metabolic health risks

What happens to your body when you eat too many ultra-processed foods

researchers found that individuals in the highest UPF intake group (60 per cent to 79 per cent of daily calories) had an 11 per cent higher likelihood of elevated hs-CRP levels

After Mounjaro success, Eli Lilly plans to launch weight-loss pill in India

Unlike injectable Mounjaro, which focuses on patients with a BMI above 35, Orforglipron is designed for the larger group of patients with a BMI of 27-34, offering an expected weight reduction of 12-16

Scientists test 4-in-1 drug that may rival Ozempic and bariatric surgery

Researchers explore next-gen obesity drug targeting four hormones at once to overcome limits of existing treatments

Will this court fight make the world's hottest weight-loss drug cheaper?

Indian pharma takes Novo Nordisk to court over patents that keep Wegovy and Ozempic out of reach - could this slash prices for millions of patients?

From stomach paralysis to vision loss: Ozempic faces over $2 bn lawsuits

Ozempic, the viral weight-loss injection, is now in the dock with $2 billion lawsuits as patients allege stomach paralysis, vision loss, and lasting health damage

Ozempic, other weight-loss drugs tied to rare, serious eye issue: Study

Non-arteritic anterior ischaemic optic neuropathy, or NAION, is a rare but devastating eye condition that occurs when blood flow to the optic nerve is suddenly reduced or blocked

Cult Fit co-founder's realistic weight loss lessons for lasting results

From better sleep to mindful hydration, Cult Fit co-founder Rishabh Telang shares six simple, science-backed weight loss tips that fit into real life, no crash diets required

Fit India Sundays on Cycle: What is it, how to locate and register?

Launched in December 2024, the weekly campaign invites people of all ages to join cycling and wellness activities, promoting fitness, sustainability, and community participation across India

Weighty issues: India's rush to make weight-loss drugs demands user caution

The global market for weight-loss drugs is estimated at $100 billion by the end of the decade

Digital health company eMed taps former X boss Linda Yaccarino as CEO

Yaccarino, one of Elon Musk's top deputies, stepped down from her role at the social media site in July

DRL to Cipla: Pharma Inc firms up plans to launch anti-obesity drugs

Push comes as patents are set to expire in March 2026

Dr Reddy's to launch obesity drug in 87 nations starting next year: CEO

The company initially plans to launch the generic version in Canada, India, Brazil, Turkey and other emerging markets, subject to patent expiry, Israeli said at a press conference

IIM Ahmedabad, Novo Nordisk India partner to boost obesity care ecosystem

The Indian Institute of Management Ahmedabad on Wednesday said it has signed an agreement with Novo Nordisk India to strengthen the obesity care ecosystem in the country for five years till 2030. The memorandum of understanding, inked on Tuesday, aims to strengthen the healthcare ecosystem in India through a multi-dimensional approach focused on non-communicable diseases (NCDs), especially obesity, the Indian Institute of Management Ahmedabad (IIMA) said in a statement. "This collaboration with Novo Nordisk India brings together healthcare and public policy, two domains where data and research can enable lasting change. At IIMA, we aim to apply our academic rigour to generate actionable insights for policymakers, healthcare professionals, and communities tackling non-communicable diseases like obesity," IIM Ahmedabad Director Professor Bharat Bhasker said. As a part of this collaboration, Novo Nordisk India (NNIPL) and IIMA will co-develop and implement impactful programmes under ..

Can Mounjaro transform obesity care? ₹50 crore sales in three months

Eli Lilly's Mounjaro has seen explosive growth since its March launch in India, with sales soaring to Rs 50 crore in three months

Can lemon water burn fat? Experts bust 15 weight loss myths you believe

From lemon water and detox drinks to skipping rice and sweating more, experts separate fat-loss facts from fiction to help you focus on what works

Obesity drug race begins: Wegovy launches in India | Novo Nordisk | Weight loss drug | Pharma sector

Danish pharma giant Novo Nordisk has brought its weight-loss drug Wegovy to India. This follows US company Eli Lilly’s launch of Mounjaro just 3 months ago.

Novo Nordisk launches Wegovy in India to rival Eli Lilly's weight-loss drug

Wegovy enters the Indian market as the first GLP-1 drug approved for both weight loss and cardiovascular risk reduction, competing with Eli Lilly's Mounjaro

Novo Nordisk launches Wegovy in India to tackle obesity and heart risk

Wegovy is India's first weekly injectable approved for both long-term weight loss and reducing heart risks in obese and overweight adults

Obesity injections may have less weight loss effect in reality: Study

Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found. Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar. The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting. "Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said. "According to our data, this could be explained by higher rates of discontinuation and lower